skip to main content

Paget mentioned in New England Journal of Medicine

24 July 2020


The James Paget has been mentioned in the New England Journal of Medicine as one of the hospitals involved in trials of a drug which aims to help patients with severe COVID-19 symptoms. 

Dexamethasone was one of the patient treatments tested at part of the natiowide RECOVERY trial that is seeking drugs and treatments which can reduce the mortality rate of COVID-19.

Recent results from the trial have show that Dexamethasone can significantly improve outcomes for some of the most severely ill hospitalised patients.

The James Paget Research team have been involved in enrolling patients to the RECOVERY trial and have been highlighted as one of the 175 NHS organisations in the UK that were part of the successful Dexamethasone study, which has now been published.

You can reach the report in the prestigious New England Journal of Medicine here; ‘